These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17434921)

  • 1. Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use.
    Chu W; Fyles A; Sellers EM; McCready DR; Murphy J; Pal T; Narod SA
    Carcinogenesis; 2007 Oct; 28(10):2139-42. PubMed ID: 17434921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular genetic characterization of tamoxifen-associated endometrial cancer.
    Prasad M; Wang H; Douglas W; Barakat RR; Ellenson LH
    Gynecol Oncol; 2005 Jan; 96(1):25-31. PubMed ID: 15589576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
    Swerdlow AJ; Jones ME;
    J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Committee Opinion No. 601: Tamoxifen and uterine cancer.
    Obstet Gynecol; 2014 Jun; 123(6):1394-1397. PubMed ID: 24848920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk.
    Rebbeck TR; Troxel AB; Wang Y; Walker AH; Panossian S; Gallagher S; Shatalova EG; Blanchard R; Bunin G; DeMichele A; Rubin SC; Baumgarten M; Berlin M; Schinnar R; Berlin JA; Strom BL
    J Natl Cancer Inst; 2006 Sep; 98(18):1311-20. PubMed ID: 16985250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study.
    DeMichele A; Troxel AB; Berlin JA; Weber AL; Bunin GR; Turzo E; Schinnar R; Burgh D; Berlin M; Rubin SC; Rebbeck TR; Strom BL
    J Clin Oncol; 2008 Sep; 26(25):4151-9. PubMed ID: 18757329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review.
    Iqbal J; Ginsburg OM; Wijeratne TD; Howell A; Evans G; Sestak I; Narod SA
    Cancer Treat Rev; 2012 Jun; 38(4):318-28. PubMed ID: 21775065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
    Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
    Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients.
    Cohen I; Bernheim J; Azaria R; Tepper R; Sharony R; Beyth Y
    Gynecol Oncol; 1999 Oct; 75(1):136-41. PubMed ID: 10502440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen, screening and new oestrogen receptor modulators.
    Neven P; Vergote I
    Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):365-80. PubMed ID: 11476559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
    Cheng WF; Lin HH; Torng PL; Huang SC
    Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
    Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
    J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
    Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
    Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use.
    Cuenca RE; Giachino J; Arredondo MA; Hempling R; Edge SB
    Cancer; 1996 May; 77(10):2058-63. PubMed ID: 8640670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of endometrial cancer risk with a functional polymorphism (Asp(327)Asn) in the sex hormone-binding globulin gene.
    Kataoka N; Cai Q; Xu WH; Xiang YB; Cai H; Zheng W; Shu XO
    Cancer; 2007 Apr; 109(7):1296-302. PubMed ID: 17315164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of endometrial cancer in asymptomatic postmenopausal breast cancer patient treated with tamoxifen: a case report.
    Sinawat S; Chiyabutra T; Kleabkaew P
    J Med Assoc Thai; 2001 Jul; 84(7):1033-6. PubMed ID: 11759963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor polymorphisms in tamoxifen-treated women with breast cancer.
    Georgopoulos NA; Adonakis GL; Fotopoulos A; Koika V; Spinos N; Saltamavros A; Keramopoulos A; Koukouras D; Decavalas G; Kourounis GS
    Gynecol Endocrinol; 2006 Apr; 22(4):185-9. PubMed ID: 16723304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women.
    Chan SS; Tam WH; Yeo W; Yu MM; Ng DP; Wong AW; Kwan WH; Yuen PM
    BJOG; 2007 Dec; 114(12):1510-5. PubMed ID: 17995495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer and duration of tamoxifen.
    Prescrire Int; 2015 Sep; 24(163):220. PubMed ID: 26417636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.